Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6511 to 6525 of 8314 results

  1. Looked-after children and young people (PH28)

    This guidance has been updated and replaced by NICE guideline NG205.

  2. Needle and syringe programmes (PH18)

    This guideline has been updated and replaced by NICE guideline PH52.

  3. Social and emotional wellbeing in primary education (PH12)

    This guideline has been updated and replaced by the NICE guideline on social, emotional and mental wellbeing in primary and secondary education (NG223).

  4. Stop smoking services (PH10)

    This guideline has been updated and replaced by NICE guideline NG92.

  5. Smoking: brief interventions and referrals (PH1)

    This guidance has been updated and replaced by NICE guideline NG92.

  6. Smoking: preventing uptake in children and young people (PH14)

    This guideline has been updated and replaced by the NICE guideline on tobacco: preventing uptake, promoting quitting and treating dependence (NG209).

  7. Workplace health: long-term sickness absence and incapacity to work (PH19)

    This guideline has been updated and replaced by NICE guideline NG146.

  8. Social and emotional wellbeing in secondary education (PH20)

    This guideline has been updated and replaced by NICE guideline on social, emotional and mental wellbeing in primary and secondary education (NG223).

  9. Immunisations: reducing differences in uptake in under 19s (PH21)

    This guideline has been replaced by NICE guideline NG218.

  10. Mental wellbeing at work (PH22)

    This guideline has been updated and replaced by NICE guideline NG212.

  11. Smoking prevention in schools (PH23)

    This guideline has been updated and replaced by the NICE guideline on tobacco: preventing uptake, promoting quitting and treating dependence (NG209).

  12. Rituximab for aggressive non-Hodgkin's lymphoma (TA65)

    After consultation the guidance has been withdrawn because it is no longer relevant to clinical practice. Rituximab is now routinely used outside its licensed indication. See NICE’s guideline on non-Hodgkin’s lymphoma.

  13. Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer (TA831)

    This guidance has been updated and replaced by NICE technology appraisal guidance 887.